The phrase "a modest efficacy of" is correct and usable in written English.
It can be used when discussing the effectiveness or performance of something in a restrained or moderate manner.
Example: "The new treatment showed a modest efficacy of reducing symptoms in patients."
Alternatives: "a limited effectiveness of" or "a slight effectiveness of".
Even high-dose interleukin-2 or interferon result only in a modest efficacy in subgroups of patients with cancers partially dependant on immunesurveillance such as advanced renal cancer or melanoma.
The Truvada trial in MSM, completed in November 2010, had a more modest efficacy of 44%.
Therefore, with only a modest (efficacy 25%) impact on the course of disease progression, DMTs show promise for prolonging life and shifting the balance in favor of milder disease and more independence for patients with Alzheimer's disease.
By dual inhibition of HER1 and HER2, lapatinib also demonstrated a modest efficacy in HER2-positive breast cancer patients with brain metastases [ 39].
A small RCT established the modest efficacy of an omega-6 EFA and essential oil-containing topical formulation (Dermoscent Essential 6 spot-on, Laboratoire de Dermo-Cosmétique Animale) for reducing clinical signs of AD (QOE 2) [ 39 ].
Three studies have also demonstrated the safety and modest efficacy of cyclosporine A in PsA [ 115– 115].
The apparent disparity in clinical efficacy of VX-770 in compound heterozygotes (ΔF508/G551D) carrying one copy of G551D CFTR and a G551D homozygote carrying two copies of G551D CFTR, as well as the modest efficacy of VX-770 seen in ΔF508 homozygotes, suggested to us that ΔF508 CFTR channels and G551D CFTR channels might differ in their thermal stabilities.
Dopaminergic mechanisms may be involved in the pathophysiology of posttraumatic stress disorder (PTSD), although the evidence for this is limited; serotonergic mechanisms are implicated largely by virtue of the modest efficacy of serotonergic drugs in the treatment of the disorder.
However, the modest efficacy of these drugs and emerging problems with anti-VEGF treatment resistance welcome the development of alternative antiangiogenic therapies.
First, this finding could explain the modest efficacy of anti-VEGF therapies in breast cancer.
